Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 13/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 13/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289843 | 0.94 | GRIA2 (0.53) | GRIA2GRIA4ALDH1A1LSSLMNA | |
| SCHEMBL8289509 | 0.93 | GRIA2 (0.54) | GRIA2GRIA4ALDH1A1 | |
| SCHEMBL8288409 | 0.93 | GRIA2 (0.55) | GRIA2GRIA4ALDH1A1MEN1KMT2A | |
| SCHEMBL8289844 | 0.93 | GRIA2 (0.54) | GRIA2GRIA4ALDH1A1MEN1KMT2A | |
| SCHEMBL8287386 | 0.93 | GRIA2 (0.48) | GRIA2GRIA4 | |
| SCHEMBL8289413 | 0.93 | GRIA2 (0.52) | GRIA2GRIA4ALDH1A1LMNA | |
| SCHEMBL8289639 | 0.90 | GRIA2 (0.68) | GRIA2GRIA4ALDH1A1MEN1KMT2A | |
| SCHEMBL13611815 | 0.88 | GRIA2 (0.53) | GRIA2GRIA4ALDH1A1MEN1KMT2A | |
| SCHEMBL8289860 | 0.88 | GRIA2 (0.51) | GRIA2GRIA4 | |
| SCHEMBL8288461 | 0.88 | GRIA2 (0.52) | GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA2 17/4885GRIA4 16/4885ALDH1A1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.